Top Markets
#1 DeFiChain DeFiChain +2,516.54%
#2 Akedo Akedo +236.37%
#3 ONFA ONFA +54.16%
#4 Metaplex Metaplex +22.52%
#5 Wrapped Krown Wrapped Krown +19.97%
#6 Osaka Protocol Osaka Protocol +18.53%
#7 Talus Network Talus Network +17.86%
#8 DODO DODO +16.79%
#9 Magma Finance Magma Finance +15.62%
#10 Black Phoenix Black Phoenix +15.03%
Coin of the day
DeFiChain DeFiChain
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Valbiotis SA Valbiotis SA

Valbiotis SA

ALVAL
Kedudukan dalam Saham #16324
Valbiotis SA engages in the research and development of health nutrition... Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases. The company develops TOTUM-63 that is in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with non-alcoholic fatty liver disease. It has a strategic partnership with Nestlé Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in Périgny, France.
Harga Saham
$0.94180721
Modal Pasaran
$22.26M
Perubahan (1 hari)
0.38%
Perubahan (1 tahun)
-14.35%
Negara
FR
Perdagangan Valbiotis SA (ALVAL)

Kategori

Healthcare
Hasil untuk Valbiotis SA (ALVAL)
Hasil pada Dec 2025 TTM: $1.06M
Menurut laporan kewangan terkini daripada Valbiotis SA, hasil semasa syarikat (TTM) ialah $1.06M. Pada tahun 2023, syarikat memperoleh hasil sebanyak $5.23M peningkatan berbanding hasil pada tahun 2022 iaitu $842.05K. Hasil ialah jumlah pendapatan keseluruhan yang dijana oleh syarikat daripada jualan barangan atau perkhidmatan. Tidak seperti keuntungan, tiada perbelanjaan ditolak.
Sejarah hasil bagi Valbiotis SA dari 2015 hingga 2026
Hasil pada akhir setiap tahun
Tahun Hasil Ubah
2026 (TTM) $1.06M 483.09%
2024 $182.10K -96.52%
2023 $5.23M 521.36%
2022 $842.05K 148.49%
2021 $338.87K -91.00%
2020 $3.77M 3,588.18%
2019 $102.10K 12.47%
2018 $90.78K 2,421.95%
2017 $3.60K -99.47%
2016 $679.71K 6,159.87%
2015 $10.86K 0.00%
Hasil untuk syarikat atau pesaing serupa
Syarikat Hasil Perbezaan Hasil Negara
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 $52.05B 4,901,516.93%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.26B 1,154,073.15%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 $14.92B 1,405,013.12%
US
UCB SA UCB SA
UCB SA
UCB.BR
 $9.08B 855,259.12%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $4.94B 465,536.55%
NL